Filing Flows › Xenetic Biosciences (XBIO) › Q2 2026
Xenetic Biosciences (XBIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Xenetic Biosciences (XBIO) reported revenue of $661K for the second quarter 2026 (Q2 2026), +12% from a year earlier and -18% from the quarter before. Operating margin was -147.1%, net loss $930K (140.7% of revenue).
Xenetic Biosciences, Q2 2026: revenue $661K (+12% year over year), operating margin -147.1%, net loss $930K, operating cash flow −$875K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $661K | -18% | +12% |
| Operating profit | −$972K | — | — |
| Net earnings | −$930K | — | — |
| Operating cash flow | −$875K | — | — |
What changed
Revenue was $661K in Q2 2026, up 12% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $1.0M, an operating margin of -147.1%. Total costs grew 24% against revenue growth of 12%. The fastest-growing cost line was General & admin (+64%). The quarter ended with a net loss of $930K, wider than the previous quarter's $456K loss.
Operating cash flow was −$875K. Non-cash charges added back $52K of share-based compensation.
Questions
What was Xenetic Biosciences' revenue in the second quarter 2026?
Xenetic Biosciences (XBIO) reported revenue of $661K for the second quarter 2026 (Q2 2026), +12% from a year earlier and -18% from the quarter before.
Was Xenetic Biosciences profitable in the second quarter 2026?
Operating loss was $972K (-147.1% of revenue) and net loss $930K.